Nasdaq · Biotech stocks database
PRQR (ProQR Therapeutics N.V.) stock: $1.35, $190.5M market cap, $104.0M cash, $92.0M EV, $167.3M fully diluted market cap. Lead program: sepofarsen (Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis), Phase 2/3. Data from Fully Diluted's biotech stocks database.
We are a clinical-stage biotechnology company advancing a pipeline ( Figure 1 ) of RNA editing therapeutics based on our proprietary Axiomer RNA-editing platform. Our lead program, AX-0810 for cholestatic diseases targeting na-taurocholate cotransporting polypeptide (“NTCP”), is currently being evaluated in a Phase 1 clinical trial in healthy volunteers.
Source: 20-F FY2025 via SEC EDGAR
| Cash | $104.0M |
|---|---|
| Debt | $5.5M |
| Net cash | $98.5M |
| Enterprise value | $92.0M |
| Basic shares | 105.4M shares |
| Fully diluted shares | 124.0M shares |
| Fully diluted market cap | $167.3M |
| Cash per share | $0.99 |
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Cap table as of 2025-12-31.
Loading PRQR daily closes…